72F fusion protein vaccine
72F fusion protein vaccine is a candidate tuberculosis vaccine created by Statens Serum Institut (SSI). The 72F fusion protein is composed of the and proteins derived from Mycobacterium tuberculosis. Phase I clinical trials were completed in 2005 and Phase II trials are awaited.
See also[]
References[]
- Kaufmann SHE, McMichael AJ (2005). "Annulling a dangerous liaison: vaccination strategies against AIDS and tuberculosis". Nature Medicine. 11 (4 suppl): S33–S44. doi:10.1038/nm1221. PMC 7095892. PMID 15812488.
 | This immunology article is a stub. You can help Wikipedia by . |
Categories:
- Tuberculosis vaccines
- Protein subunit vaccines
- Immunology stubs